Multiple gastrointestinal stromal tumors typically occur in familial form associated with KIT receptor tyrosine kinase or platelet-derived growth factor receptor-alpha (PDGFRA) germline mutations, but may also develop in the setting of type 1 neurofibromatosis. The molecular abnormalities of gastrointestinal stromal tumors arising in neurofibromatosis have not been extensively studied. We identified three patients with type 1 neurȯ -fibromatosis and multiple small intestinal stromal tumors. Immunostains for CD117, CD34, desmin, actins, S-100 protein, and keratins were performed on all of the tumors. DNA was extracted from representative paraffin blocks from separate tumor nodules in each case and subjected to a nested polymerase chain reaction, using primers for KIT exons 9, 11, 13, and 17 and PDGFRA exons 12 and 18, followed by direct sequencing. The mean patient age was 56 years (range: 37-86 years, male/female ratio: 2/1). One patient had three tumors, one had five, and one had greater than 10 tumor nodules, all of which demonstrated histologic features characteristic of gastrointestinal stromal tumors and stained strongly for CD117 and CD34. One patient died of disease at 35 months, one was disease free at 12 months and one was lost to follow-up. DNA extracts from 10 gastrointestinal stromal tumors (three from each of two patients and four from one patient) were subjected to polymerase chain reactions and assessed for mutations. All of the tumors were wild type for KIT exons 9, 13, and 17 and PDGFRA exons 12 and 18. Three tumors from one patient had identical point mutations in KIT exon 11, whereas the other tumors were wild type at this locus. We conclude that, although most patients with type 1 neurofibromatosis and gastrointestinal stromal tumors do not have KIT or PDGFRA mutations, KIT germline mutations might be implicated in the pathogenesis of gastrointestinal stromal tumors in some patients.
Gastrointestinal stromal tumors (GIST) are mesenchymal tumors that arise throughout the gastrointestinal tract and, rarely, in the mesentery or retroperitoneum. They are characterized by strong immunohistochemical staining for CD117 and most contain activating mutations in the KIT receptor tyrosine kinase, particularly at exons 9, 11, 13, and 17. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Approximately one-third of tumors that are wild type at the KIT gene harbor mutations in the juxtamembrane and tyrosine kinase domains of a related tyrosine kinase receptor, platelet-derived growth factor receptor-alpha (PDGFRA). [11] [12] [13] In most cases, GISTs are sporadic in nature, however, they may occur as multiple lesions in familial forms associated with KIT or PDGFRA germline mutations. [14] [15] [16] [17] [18] [19] In these situations, GISTs arise in a background of interstitial cell of Cajal hyperplasia and may be associated with systemic manifestations including skin hyperpigmentation and mast cell disorders. 14, 15, 20, 21 An association between the development of multiple GISTs and type 1 neurofibromatosis has also been established, however, the molecular abnormalities of GISTs arising in this setting have not been elucidated and studies assessing their molecular features are limited. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Therefore, the purpose of this study was to evaluate a series of multiple GISTs in patients with type 1 neurofibromatosis, in an effort to identify any distinctive morphologic features of these tumors and molecular abnormalities in the KIT and PDGFRA genes.
Materials and methods

Study Group
The study group consisted of three patients with type 1 neurofibromatosis and multiple GISTs who were prospectively identified from the UMass Memorial Health Care Department of Pathology (two cases) and the Department of Pathology of the Massachusetts General Hospital (one case), during the time period of 1999-2003, inclusively. The diagnostic criteria for type 1 neurofibromatosis were derived from the National Institutes of Health consensus statement and included at least two of the following features: six or more café au lait spots greater than 15 mm in diameter in a postpubertal patient, two or more neurofibromas of any type or at least one plexiform neurofibroma, freckling in the axillary or inguinal regions, and the presence of an optic glioma, two or more hamartomas of the iris (Lisch nodules), bone lesions such as sphenoid dysplasia or thinning of the cortex of long bones, or at least one first-degree relative with type 1 neurofibromatosis as defined by the above criteria. 33 The presence of any other neoplasms commonly associated with type 1 neurofibromatosis, such as meningioma, colorectal carcinoma, ampullary gangliocytic paraganglioma, ampullary somatostatinoma, and pheochromocytoma was also noted. Pathologic materials from previous or subsequent specimens documenting the presence of type 1 neurofibromatosis were available for review in all cases. All of the patients underwent complete surgical resection of all of their GISTs at the time of the diagnostic procedure. Clinical information regarding the patients' gender, age, medical history, presenting symptoms, and outcome was obtained from the patients' physicians, medical records, surgical pathology reports, and operative notes.
Pathologic and Immunohistochemical Evaluation
Hematoxylin and eosin-stained slides cut from routinely processed (10% buffered formalin) paraffin-embedded tissue sections were available for review in all cases. Immunostains for a panel of antibodies (Table 1) were utilized to evaluate the tumors and were performed on 4 mm thick formalinfixed paraffin-embedded tissue sections using the standard avidin-biotin complex technique. Sections of normal colon served as positive controls for vimentin, muscle actins, desmin, keratin, S-100 protein, CD34, and CD117.
DNA Isolation
Paraffin-embedded tissue blocks from 10 tumors were evaluated. Five to six 5-mm sections were cut from each paraffin block. The sections were deparaffinated by adding 1200 ml of xylene, vortexing for 1 min and then centrifuging at full speed for 10 min at room temperature. The supernatant was removed and 1200 ml of ethanol was added to each sample. The samples were again vortexed for 1 min and centrifuged at full speed for 10 min. After removing the supernatant, the samples were allowed to dry at room temperature overnight. Total cellular DNA was isolated using the protocol accompanying the Qiagen DNeasyt Tissue Kit (Qiagen, Inc., Valencia, CA, USA).
Polymerase Chain Reaction (PCR) Amplification and Sequencing
After isolation, genomic DNA from each case was subjected to PCR using Platinum Taq DNA Polymerase (Invitrogen Inc., Carlsbad, CA, USA) and primers for KIT exons 9, 11, 13, and 17 as well as PDGFRA exons 12 and 18 ( Table 2 ). The PCR conditions used for amplification of various KIT and PDGFRA exons were as follows: the samples were incubated for 4 min at 941C, followed by 35 cycles of 941C for 30 s, the relevant annealing temperature for 30 s, 721C for 30 s; and finally incubated at 721C for 30 min. The PCR products were identified by agarose gel electrophoresis and purified using the Qiaquick PCR Purification Kit (Qiagen, Inc., Valencia, CA, USA) prior to sequencing.
All sequencing reactions were performed from both forward and reverse directions using a 10 pmol PCR-primer concentration per reaction. Each ABI sequence was compared to the National Center for Biotechnology Information (NCBI) Human KIT and PDGFRA gene nucleotide sequences to determine the presence, type, and location of a mutation. In those cases that contained mutations, the PCR amplification and sequencing studies were repeated to confirm the results. 
Results
Study Cases
Case 1
The patient was a 48-year-old man with a history of type 1 neurofibromatosis who presented with right upper quadrant pain, night sweats, and a 20 pound weight loss. He had multiple cutaneous neurofibromas and pigmented macules ranging up to 4 cm in diameter. His mother, brother, and sister all suffered from type 1 neurofibromatosis, but lacked gastrointestinal manifestations of this disease. Radiographic imaging revealed an 8 cm mass in the duodenum as well as greater than 10 serosal and mural nodules in the small intestine, all of which were resected and determined to be GISTs. Based upon morphologic differences between the largest and smaller tumors in the small intestine, the lesions were interpreted to represent synchronous primary lesions rather than metastases. The patient developed recurrent GIST in the retroperitoneum 14 months after resection and died 35 months after surgical resection. The primary findings at autopsy included disseminated GIST involving the lungs, liver, retroperitoneum, small intestine, and pancreas, as well as numerous cutaneous neurofibromas ( Figure 1 ).
Case 2
This 86-year-old woman presented with increasing abdominal pain and abdominal fullness secondary to a 10 cm ovarian cyst. Upon physical examination, she was found to have innumerable fleshy cutaneous nodules involving the scalp, face, trunk, and limbs with sparing of the mucosal surfaces. She had one son that was similarly afflicted with cutaneous lesions. The patient was taken to the operating room for a hysterectomy and bilateral salpingo-oophorectomy procedure, at which time she was noted to have three mural and subserosal nodules involving the small intestine, ranging from 0.5 to 2.5 cm in diameter, all of which were resected. At the time of the procedure, one of the cutaneous lesions was also sampled and found to be a neurofibroma. Pathologic evaluation of the small intestinal tumors confirmed the diagnosis of multiple GISTs. The patient was subsequently lost to follow-up.
Case 3
This patient was a 48-year-old male with moderate cognitive deficits and type 1 neurofibromatosis characterized by the presence of hundreds of cutaneous neurofibromas and pigmented macules over the entire skin surface. He presented for colonoscopic evaluation following completion of chemoradiation therapy for a T3, N1 rectal adenocarcinoma resected 18 months prior. Upon colonoscopy, he was found to have a suspicious, ulcerative lesion in the sigmoid colon and subsequently underwent surgical exploration and a complete colectomy. At the time of laparotomy, the patient was found to have five serosal tumors on the distal ileum, which ranged from 0.5 to 3 cm in diameter, all of which were resected. The colonic mass was an invasive adenocarcinoma and the ileal tumors were GISTs. The patient subsequently underwent upper endoscopic evaluation of the ampulla of Vater and was found to have a duodenal somatostatinoma. At 6 months after resection of the GISTs, the patient developed multiple liver metastases from his colonic adenocarcinoma, but did not have any evidence of recurrent GIST 12 months after surgical resection.
Pathologic Findings
One patient had three synchronous GISTs, one had five tumors, and one had greater than 10 tumor nodules, all of which were located in the duodenum or small intestine. The mean tumor size was 0.8 cm (range: 0.3-8.0 cm). Although the largest tumor had hEx18-R TGAAGGAGGATGAGCCTGACC a heterogenous cut surface with areas of hemorrhage and cystic degeneration, all of the other lesions were relatively small, homogeneous, and tan-white ( Figure 2) . All of the tumors were composed predominantly of spindle cells arranged in short intersecting fascicles or organoid nests, similar to sporadic GISTs. Although the largest tumor was overtly malignant with 49 mitoses/10 high-power fields, severe cytologic atypia, and necrosis (Case 1); all of the others were relatively low grade, with inconspicuous mitotic activity (o5 mitoses/50 highpower fields) and bland nuclear features ( Figure 3) . In most instances, the tumors were hypocellular with abundant hyalinized matrix, which was calcified in one case. In one case (Case 2), aggregates of hyperplastic interstitial cells of Cajal were present at the peripheries of the tumors and merged imperceptibly with the smooth muscle fibers of the muscularis propria, but no obvious hyperplasia of the interstitial cells of Cajal within the myenteric plexus was identified between the tumors (Figure 4) . The immunohistochemical results are summarized in Table 3 . All of the GISTs demonstrated diffuse positivity for CD117 and CD34 ( Figure 5) . None of the tumors expressed desmin, smooth muscle actin, muscle-specific actin, S-100 protein, or keratin markers.
Molecular Studies
The results of the PCR and DNA sequencing analyses are enumerated in Table 4 . Briefly, 10 tumors (3, 3, and 4 nodules from Cases 1, 2, and 3, respectively, including the malignant tumor from Case 1) were wild type for exons 9, 13, and 17 of the KIT gene and exons 12 and 18 of the PDGFRA gene. Identical point mutations were identified in three tumors from one patient (Case 1) in exon 11 of the KIT gene, whereas all of the other tumors were wild type at this locus ( Figure 6 ).
Discussion
In this study, we evaluated the clinical, pathologic, and molecular features of a series of multiple GISTs from patients with clinically and pathologically confirmed diagnoses of type 1 neurofibromatosis. All of the tumors stained strongly and diffusely for CD117 and CD34, were negative for desmin, actins, S-100 protein, and keratins, and were morphologically indistinguishable from sporadic GISTs. We evaluated 10 tumors for the presence of KIT and PDGFRA mutations at loci in which mutations have been previously described in sporadic GISTs. 10, 34, 35 We found identical point mutations at KIT exon 11 in three different tumors from one patient, including a malignant GIST, whereas all of the tumors from the other two patients were wild type at this locus. All of the tumors were wild type at all of the other loci evaluated. Our results indicate that KIT mutations may play a role in the pathogenesis of GISTs among some patients with type 1 neurofibromatosis. However, most GISTs associated with type 1 neurofibromatosis reported to date do not have mutations in the KIT gene and likely arise via a different pathogenetic mechanism than that of sporadic GISTs. 31 GISTs are unique mesenchymal tumors of the gastrointestinal tract with characteristic morphologic, immunophenotypic, and molecular features. 3, 4, 11, [36] [37] [38] [39] [40] [41] [42] Most sporadic tumors arise in the stomach, followed in frequency by the small intestine and, more rarely, the colon, esophagus, anus, biliary structures, and extraintestinal soft tissues. The morphologic and immunophenotypic features of GISTs have been thoroughly described in the literature: the majority show strong and diffuse staining for CD117 and CD34, but are typically negative for desmin and S-100 protein. 6, 8, 36, 38, [40] [41] [42] Approximately 75-80% of GISTs harbor activating mutations in the KIT tyrosine kinase receptor, particularly in exons 9 (extracellular domain), 11 (juxtamembrane domain), 13 (TK I domain), and 17 (TK II domain); whereas many GISTs that lack KIT mutations contain intragenic activating mutations in a related tyrosine kinase receptor, PDGFRA, in exons 12 or 18. 10, 11, 13, 39, 43, 44 Most GISTs occur in a sporadic fashion. However, multifocal GISTs usually arise in specific settings, such as KIT or PDGFRA germline mutations, and in patients with intestinal neuronal dysplasia or type 1 neurofibromatosis. [14] [15] [16] [17] [18] [19] [20] [21] 27, 31, 32, 35, [45] [46] [47] [48] [49] [50] [51] These patients usually develop tumors in the small intestine, which may be associated with hyperplasia of the interstitial cells of Cajal. Patients with KIT germline mutations may also have skin or mucous membrane hyperpigmentation as well as mast cell proliferations and, similar to sporadic tumors, most of their GISTs contain mutations in exon 11, although mutations involving exons 13 and 17 have been described as well. 5, [15] [16] [17] [18] [19] 21 Type 1 neurofibromatosis is a relatively common autosomal dominant inherited disorder with a prevalence of approximately one in 3000 live births in Western countries. 33 The syndrome results from inherited or spontaneous germline mutations in the NF gene located at chromosome 17q11.2, which encodes the tumor suppressor gene, neurofibromin. 26, 32, [52] [53] [54] [55] In addition to multiple cutaneous and deep-seated neurofibromas, patients with type 1 neurofibromatosis develop other evidence of the disease, including skin manifestations (axillary freckling, café au lait spots), neurological disorders (cognitive deficits and seizures), extraintestinal neoplasms (pheochromocytomas, tumors of the central nervous system), and neoplasms of the gastrointestinal tract (ampullary adenomas and adenocarcinomas, somatostatinomas, gangliocytic paragangliomas, colorectal carcinomas, and GISTs). 26, [31] [32] [33] The association between GISTs and type 1 neurofibromatosis has been well established, however, the frequency with which GISTs occur in this setting is not entirely clear. [22] [23] [24] [28] [29] [30] 51, [56] [57] [58] In one autopsy study of greater than 27,000 patients, 3/12 (25%) patients with type 1 neurofibromatosis had multiple GISTs, whereas clinical studies indicate that GISTs are identified in 5-25% of patients with type 1 neurofibromatosis. 25, 27, 59 The GISTs in these patients have a predilection for the small intestine; tumors originating in the stomach and colon are less common. Unfortunately, most reports of patients with multiple GISTs and type 1 neurofibromatosis predate the recent technical advances in DNA extraction from paraffin-embedded tissues and, therefore, lack information regarding potential mutations in genes that have been implicated in the pathogenesis of GISTs.
In 2003, Kinoshita et al evaluated a series of GISTs from patients with type 1 neurofibromatosis for the presence of KIT mutations. 31 In that study, the authors evaluated KIT exons 9, 11, 13, and 17 in 29 GISTs from seven patients with type 1 In keeping with this hypothesis, two of the patients in the current study lacked KIT and PDGFRA mutations in multiple loci evaluated, but one had multiple GISTs that shared the same V559D point mutation in the juxtamembrane domain (KIT exon 11) that has been previously reported in two different studies of multiple GISTs from patients with germline KIT mutations. 14, 18 Given this result, as well as the occurrence of cutaneous pigmentation and multiple GISTs in patients with germline KIT mutations, one might argue that the patient reported herein did not have type 1 neurofibromatosis, but suffered from a germline mutation in the KIT gene. However, we believe that the clinical and pathologic findings in this case support the diagnosis of type 1 neurofibromatosis. This patient had multiple pathologically confirmed neurofibromas and pigmented cutaneous macules (café au lait spots), as well as several first-degree relatives similarly affected with skin manifestations of the disease, thereby satisfying the clinical criteria for type 1 neurofibromatosis. 33 Moreover, none of the other afflicted family members developed multiple GISTs, suggesting that they did not have germline KIT mutations. Therefore, we believe that our results reflect that only a limited number of type 1 neurofibromatosis patients with multiple GISTs have been evaluated using molecular techniques and, thus, it is possible, if not likely, that future studies may identify KIT mutations in a subset of type 1 neurofibromatosis patients with multiple GISTs.
In summary, we report the clinical, pathologic and molecular features of a series of patients with type 1 neurofibromatosis who also had multiple GISTs. Our results indicate that GISTs occurring in this setting are morphologically and immunohistochemically similar to sporadic GISTs. The results of our molecular studies demonstrate the presence of the same KIT mutation in multiple GISTs from one patient and wild-type KIT and PDGFRA in the remaining two patients. We conclude that most GISTs that occur in association with type 1 neurofibromatosis do not have the same molecular abnormalities present in sporadic GISTs and, therefore, likely arise via different pathogenetic mechanisms. Some of these tumors, however, do have KIT mutations, suggesting that this pathway is active in the evolution of GISTs in some patients with type 1 neurofibromatosis.
